Intraparenchymal hemorrhage

Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases

Retrieved on: 
Wednesday, April 3, 2024
Hereditary hemorrhagic telangiectasia, Telangiectasia, Biotechnology, Blood, Disease, Atlas, Patient, Lung, Stroke, Viking Global Investors, Death, Artery, Chiari malformation, Rupture, Intraparenchymal hemorrhage, Heart failure, Lightspeed Venture Partners, Therapy, TGF, Antibody, Bleeding, Heart, Pharmacology, Unified school district, HHT, PAH, Atlas Venture, Pulmonary hypertension, Pharmaceutical industry

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, launched today with $128 million in financing. The Series A was co-led by BVF Partners and Atlas Venture, with participation from Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, Velosity Capital, and Checkpoint Capital. Diagonal was co-founded by Chief Executive Officer, Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital. The financing will support further advancement of the company’s proprietary DIAGONAL platform and pipeline of novel therapeutics to value-creating milestones, including its lead program for the treatment of hereditary hemorrhagic telangiectasia (HHT), a severely debilitating bleeding disorder with limited therapeutic options, through clinical proof-of-concept. Diagonal's agonist antibody activates a receptor complex in the TGF-β superfamily genetically impaired in HHT patients. In preclinical models of HHT, Diagonal's agonist antibodies prevent and reverse the formation of pathological vascular malformations.

Key Points: 
  • Diagonal was co-founded by Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital.
  • CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, launched today with $128 million in financing.
  • Diagonal was co-founded by Chief Executive Officer, Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital.
  • In preclinical models of HHT, Diagonal's agonist antibodies prevent and reverse the formation of pathological vascular malformations.

Virginia Milk Bank Seeks Donors for Hospitalized Babies

Retrieved on: 
Wednesday, March 20, 2024
Breast milk, Jaundice, Retinopathy, Nutrient, Lactation, Disease, Memory, Short bowel syndrome, CHKD, Risk, Necrotizing enterocolitis, Hospital, Milk, American Academy, Infant, Death, NICU, Life, Protein, Kidney disease, Intraparenchymal hemorrhage, Woman, Holiday, Antibody, Oxygen, Premature, Paratriathlon, Charli, ROP, Pediatrics (journal), Pediatrics, Dairy

Knowing that her breast milk was the best nutrition for Charli, Moultrie tried pumping to get her milk supply started.

Key Points: 
  • Knowing that her breast milk was the best nutrition for Charli, Moultrie tried pumping to get her milk supply started.
  • After two weeks of consistently pumping with scant results, Moultrie was grateful to learn that Charli could receive safe, pasteurized human milk through the hospital's donor milk bank.
  • The milk bank also has a legacy program for women who have lost a baby but want to donate their milk to help other infants.
  • “But there are times around the holidays and during the summer when we only have enough milk for hospitalized babies.”
    This means the milk bank is not always able to provide milk to babies who have been discharged from the hospital with a doctor’s prescription for pasteurized donor human milk.

Arctic Therapeutics and Nacuity Pharmaceuticals Announce European Medicines Agency Approval to Initiate First Clinical Trial of AT-001 (NPI-001) for the Treatment of HCCAA

Retrieved on: 
Tuesday, March 12, 2024
Retinitis pigmentosa, Disease, Partnership, Tablet, SVP, Stroke, Deficit spending, EMA, Cystinosis, GMP, European Medicines Agency, Clinical trial, Intraparenchymal hemorrhage, NACA, Safety, CSO, Cataract, Usher syndrome, Dementia, Oxidative stress, Amyloid, Service provider, Pharmaceutical industry

Current treatment options are severely limited, focusing primarily on symptom management rather than addressing the underlying cause of the disease.

Key Points: 
  • Current treatment options are severely limited, focusing primarily on symptom management rather than addressing the underlying cause of the disease.
  • “EMA's approval paves the way for a comprehensive investigation into the safety and efficacy of a novel therapeutic approach designed to halt or reverse the progression of HCCAA.
  • Nacuity is also currently evaluating NPI-001 in Phase 1/2 clinical trials in Australia for retinitis pigmentosa associated with Usher syndrome and cystinosis.
  • “Our proprietary NPI-001 has potential to address the myriad diseases and conditions where oxidative stress plays a role.

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

Retrieved on: 
Friday, March 22, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, SMMT, Intraparenchymal hemorrhage, Sun, EGFR, Central European Time, Metastasis, ELCC, Progression-free survival, Anaplastic lymphoma kinase, Constipation, Brain, Drug, HKEX, Safety, Anemia, Phase, Summit, TKI, Time in Europe, PFS, ALK, Pharmaceutical industry

The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.

Key Points: 
  • The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.
  • This analysis consisted of the 35 patients with advanced or metastatic NSCLC who had asymptomatic brain metastases at baseline; 28 patients were treated with ivonescimab plus chemotherapy in AK112-201, and seven patients were treated with monotherapy ivonescimab in AK112-202.
  • Patients across both cohorts experienced an intracranial response rate of 34%, and eight patients (23%) experienced a complete response by RANO criteria.
  • The most frequent TEAEs were anemia and decreased neutrophil counts in squamous patients and anemia and constipation in non-squamous patients.

Viz.ai Announces Six Clinical Studies that Further Validate Impact of Viz™ Neuro Suite on Patient Care

Retrieved on: 
Wednesday, February 7, 2024
Software, Research, General Health, Technology, Medical Devices, Infectious Diseases, Hospitals, Artificial Intelligence, Health Technology, Clinical Trials, Science, Neurology, Health, Shift, CNN, Conference, ISC, Atrial fibrillation, DTG, Neurosurgery, Workflow, FAHA, Diagnosis, ICM, Aneurysm, Intraparenchymal hemorrhage, AI, MLS, Automation, MD, Single Center, Abstract (summary), Stroke, Viz, ICH, Patient, Groin, Triage, Intervention, Artificial intelligence, CSC, UIA, Intracranial hemorrhage, Associate, University of Kentucky, University, McGovern Medical School, Ambient occlusion, Medical device

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.
  • “As a leader in AI-powered stroke detection and care coordination, Viz.ai does not rest on what we have done, but instead continues to invest in proving the accuracy and impact of our comprehensive Viz Neuro Suite,” said Molly Madziva Taitt, VP, Global Clinical Affairs.
  • This study is the first of its kind to assess the impact of AI in the acute stroke workflow based on user engagement.
  • For more information on the Viz Neuro Suite, visit https://www.viz.ai/neuro .

KPMG in Canada reinforces employee and community commitment to People with Disabilities

Retrieved on: 
Wednesday, January 31, 2024
PTSD, Multiple sclerosis, Disability, Research, Fear, Person, Statistics Canada, Friends, Caregiver, Spectrum, Canada Act 1982, CPA, Ageing, Rheumatoid arthritis, Diversity, KPMG, Action plan, Employment, Crohn's disease, Paralysis, Epilepsy, Accessible Canada Act, Bleeding, Post-traumatic stress disorder, Intraparenchymal hemorrhage, Culture, Workplace, Disease, CFA, Social isolation, Organization, Residential care

"The reality is, People with Disabilities still face physical, cultural, and attitudinal barriers in the Canadian workplace," says Rob Davis, Chief Inclusion, Diversity and Equity Officer, at KPMG in Canada.

Key Points: 
  • "The reality is, People with Disabilities still face physical, cultural, and attitudinal barriers in the Canadian workplace," says Rob Davis, Chief Inclusion, Diversity and Equity Officer, at KPMG in Canada.
  • As outlined in the plan, KPMG will create a Disability Inclusion Action Plan Steering Group to oversee the implementation of 40-plus actions and provide ongoing feedback.
  • People with Disabilities are an untapped pool of talent that could help Canada close the labour skills gap.
  • "Many with non-apparent disabilities hide them for fear of being stigmatized or hurting their chances of employment or promotion.

Huize Achieved a 98.6% Customer Satisfaction Rate for Online Customer Services and Helped over 1 Million Families Resolve Claims in 2023

Retrieved on: 
Thursday, January 18, 2024
Trust, Policy, Customer service, Intraparenchymal hemorrhage, Sudden death, Insurance, Accident, Poisoning, RMB, Cancer

According to the Customer Service Report, Huize achieved a 98.6% customer satisfaction rate for online customer services and a 99.5% satisfaction rate for teleservices during the year.

Key Points: 
  • According to the Customer Service Report, Huize achieved a 98.6% customer satisfaction rate for online customer services and a 99.5% satisfaction rate for teleservices during the year.
  • The reports revealed that in 2023, Huize served more than one million families with coverage from 11 million insurance policies.
  • In terms of claim settlement services, it showed that Huize provided assistance with 92,000 insurance claims, with a total claim settlement amount of RMB570 million.
  • We are incredibly proud of the high rate of satisfaction reported by customers who used our online services and teleservices in 2023.

Global Intracranial Pressure Monitoring Devices Market Forecast Report to 2028, Featuring Integra LifeSciences, Medtronic, IRRAS, RAUMEDIC, Vivonics, Brain4Care, Luciole Medical& TKB - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 24, 2024
Health, Medical Devices, Hospitals, Surgery, Other Science, General Health, Science, Sleep, Brain damage, Patient, TBI, Hospital, Trauma, Infection, Research, Incidence, Cloud computing, Intraparenchymal hemorrhage, Application, ICP, Accident, Developed country, DSM-IV codes, AI, Government, Public, Intracranial pressure, Safety, COVID-19, Medicine, Bleeding, Organization, Data analysis, Ageing, Diagnosis, Prevalence, Medical device

The global Intracranial pressure (ICP) monitoring device market value stood at US$1.68 billion in 2022, and is expected to reach US$2.52 billion by 2028.

Key Points: 
  • The global Intracranial pressure (ICP) monitoring device market value stood at US$1.68 billion in 2022, and is expected to reach US$2.52 billion by 2028.
  • The global intracranial pressure monitoring market is moderately fragmented, with increasing number of large and medium sized players striving to gain a significant market share.
  • New and inexpensive products are being introduced by top companies in the intracranial pressure monitoring devices market to flourish in unexplored regions & help the industry expand.
  • The key players of the global intracranial pressure monitoring market are:

Household Income and Health Insurance Among Factors in Decision to Withdraw Life Support After Hemorrhagic Stroke

Retrieved on: 
Thursday, January 18, 2024
Koto, Stroke, Death, Roger Hawkins (drummer), Patient, NYU Langone Health, Research, Medicaid, Bleeding, RN, BSN, Health, Intraparenchymal hemorrhage, Medicare, Rehabilitation, Religion, NYU, MSN, Neurosurgery, Coma, Neurology, Blood, Catholic Church, Brain, Intracerebral hemorrhage, Physician, Pharmaceutical industry

Unlike ischemic stroke, which is caused by blocked blood vessels that can be cleared in many cases, hemorrhagic strokes are more often deadly.

Key Points: 
  • Unlike ischemic stroke, which is caused by blocked blood vessels that can be cleared in many cases, hemorrhagic strokes are more often deadly.
  • By contrast, being Black and having private insurance were factors tied to a lower likelihood of life support being withdrawn.
  • Among hospitalized hemorrhagic stroke patients, Blacks made up 7% of those who had life support withdrawn but counted for 18% of those who maintained life support.
  • Similarly, while 37% had private health insurance, only 20% of those who decided to withdraw life support had private insurance.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Retrieved on: 
Friday, January 12, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Histopathology, Weight loss, Gynaecology, Bevacizumab, Cisplatin, Hypothyroidism, University, Cancer, Risk, COVID-19, Diarrhea, Hyperthyroidism, Brachytherapy, Neoplasm, Perforated ulcer, Hepatitis, FIGO, CRT, Pyelonephritis, Colitis, Vagina, ClinicalTrials.gov, PD-L1, RECIST, Disease, Patient, Fever, CPS, Chemoradiotherapy, Vomiting, MRK, Death, Nephritis, Progression-free survival, OS, Radiation, Anemia, Survival, EBRT, Abdominal pain, Intraparenchymal hemorrhage, Uterus, Cervical cancer, Constipation, PFS, Fatal, Obstetrics, Hematopoietic stem cell transplantation, Pneumonitis, Nausea, Pelvic pain, Dysuria, Fatigue, GOG, Arm, Rash, Food, Merck & Co., Sepsis, Toxicity, News, Urinary tract infection, Appetite, Pharmaceutical industry

Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

Key Points: 
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • “Building on the established role of KEYTRUDA in advanced cervical cancer, KEYTRUDA plus chemoradiotherapy is now the first anti-PD-1-based regimen approved in the U.S. for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer regardless of PD-L1 expression,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.
  • The trial enrolled 1,060 patients with cervical cancer who had not previously received any definitive surgery, radiation, or systemic therapy for cervical cancer.
  • In the exploratory subgroup analysis of 596 patients with FIGO 2014 Stage III-IVA disease, 61 patients (21%) in the KEYTRUDA plus CRT arm (n=293) experienced a PFS event versus 94 patients (31%) in the placebo plus CRT arm (n=303).